Therese Bittermann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Therese Bittermann has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Peter L. Abt
Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
10 shared publications David S. Goldberg
Division of Digestive Health and Liver Diseases, Department of Medicine, Miller School of Medicine at the University of Miami, Miami, USA
9 shared publications- Marina Serper
Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
8 shared publications K. Rajender Reddy
Department of Medicine, Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
7 shared publicationsDouglas E. Schaubel
Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, USA
6 shared publications- Ethan M. Weinberg
Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
6 shared publications
Latest Publications
- 22 October 2026
- Published by Wolters Kluwer Health in Hepatology
AASLD AGA clinical Practice Guideline on management of primary biliary cholangitis
Background & Aims: Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease associated with progressive fibrosis, cirrhosis, liver transplantation, and premature mortality. Despite effective therapies, important challenges remain in the diagnosis and management of PBC, including identification of antimitochondrial antibody–negative disease, assessment of response to ursodeoxycholic acid (UDCA), risk stratification, treatment of patients with inadequate response, management of cholestatic pruritus, and prevention of recurrent disease after liver transplantation. The aim of this guideline was to develop evidence-based recommendations addressing these key areas of clinical care. Methods: The American Gastroenterological Association (AGA) and the American Association for the Study of Liver Diseases (AASLD) convened a multidisciplinary panel to develop clinical practice recommendations for adults with PBC. Systematic reviews were performed for 6 prioritized clinical questions. The Grading of Recommendations Assessment, Development and Evaluation framework was used to prioritize clinical outcomes and assess evidence, and its Evidence to Decision Framework was used to develop recommendations. Results: The guideline panel agreed on 6 recommendations. These recommendations address the use of PBC-specific antinuclear antibodies in antimitochondrial antibody–negative suspected PBC, UDCA as first-line therapy, liver stiffness measurement for prognostication, peroxisome proliferator–activated receptor agonists for patients with inadequate response or intolerance to UDCA, linerixibat for moderate to severe pruritus, and UDCA prophylaxis post-transplantation to reduce disease recurrence. The certainty of evidence ranged from moderate to very low. Conclusions: The guideline emphasizes early diagnosis, optimization of first-line therapy, risk-based treatment escalation, symptom management, and prevention of post-transplantation disease recurrence to improve patient outcomes and quality of life.
- 22 October 2026
- Published by Wolters Kluwer Health in Hepatology
AASLD AGA clinical Practice Guideline on management of primary biliary cholangitis
Background & Aims: Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease associated with progressive fibrosis, cirrhosis, liver transplantation, and premature mortality. Despite effective therapies, important challenges remain in the diagnosis and management of PBC, including identification of antimitochondrial antibody–negative disease, assessment of response to ursodeoxycholic acid (UDCA), risk stratification, treatment of patients with inadequate response, management of cholestatic pruritus, and prevention of recurrent disease after liver transplantation. The aim of this guideline was to develop evidence-based recommendations addressing these key areas of clinical care. Methods: The American Gastroenterological Association (AGA) and the American Association for the Study of Liver Diseases (AASLD) convened a multidisciplinary panel to develop clinical practice recommendations for adults with PBC. Systematic reviews were performed for 6 prioritized clinical questions. The Grading of Recommendations Assessment, Development and Evaluation framework was used to prioritize clinical outcomes and assess evidence, and its Evidence to Decision Framework was used to develop recommendations. Results: The guideline panel agreed on 6 recommendations. These recommendations address the use of PBC-specific antinuclear antibodies in antimitochondrial antibody–negative suspected PBC, UDCA as first-line therapy, liver stiffness measurement for prognostication, peroxisome proliferator–activated receptor agonists for patients with inadequate response or intolerance to UDCA, linerixibat for moderate to severe pruritus, and UDCA prophylaxis post-transplantation to reduce disease recurrence. The certainty of evidence ranged from moderate to very low. Conclusions: The guideline emphasizes early diagnosis, optimization of first-line therapy, risk-based treatment escalation, symptom management, and prevention of post-transplantation disease recurrence to improve patient outcomes and quality of life.
- Open Access
- 21 September 2026
- Published by Wolters Kluwer Health in Liver Transplantation
MELD-based allocation disproportionately prioritizes alcohol-associated hepatitis for liver transplant
Early liver transplantation (LT) is increasingly being adopted as a treatment for alcohol-associated hepatitis (AAH), but the optimal strategy for incorporating AAH into the existing organ allocation framework remains unclear. This retrospective cohort study used the United Network for Organ Sharing database (January 1, 2018 to December 31, 2024) to compare adults waitlisted for first-time, single-organ LT for AAH with those with other alcohol-associated liver disease (ALD) and non-ALD. During the study period, waitlisting and LT for AAH increased more than 6-fold, with 98.2% of centers performing LT for this indication. Compared with other ALD and non-ALD, patients with AAH experienced lower waitlist mortality (8.2% vs. 12.6% and 19.3%, respectively; p p p =0.003 and adjusted HR=1.86 with p p =0.66). Across all MELD categories, non-ALD was associated with higher waitlist mortality than AAH (HR 1.83–3.23; all p ≤0.005), while other ALD was associated with higher mortality in most MELD strata ( p p =0.53), while international normalized ratio was a stronger predictor of mortality in AAH than other LT indications (HR=1.95 for AAH vs. HR=1.14 for other ALD vs. HR=1.23 for non-ALD; all p <0.001). Patients with AAH are disproportionately prioritized under the current organ allocation system, underscoring the need to revise the allocation practices to ensure equitable LT access.
- 21 September 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Open AccessMELD-based allocation disproportionately prioritizes alcohol-associated hepatitis for liver transplant
Early liver transplantation (LT) is increasingly being adopted as a treatment for alcohol-associated hepatitis (AAH), but the optimal strategy for incorporating AAH into the existing organ allocation framework remains unclear. This retrospective cohort study used the United Network for Organ Sharing database (January 1, 2018 to December 31, 2024) to compare adults waitlisted for first-time, single-organ LT for AAH with those with other alcohol-associated liver disease (ALD) and non-ALD. During the study period, waitlisting and LT for AAH increased more than 6-fold, with 98.2% of centers performing LT for this indication. Compared with other ALD and non-ALD, patients with AAH experienced lower waitlist mortality (8.2% vs. 12.6% and 19.3%, respectively; p p p =0.003 and adjusted HR=1.86 with p p =0.66). Across all MELD categories, non-ALD was associated with higher waitlist mortality than AAH (HR 1.83–3.23; all p ≤0.005), while other ALD was associated with higher mortality in most MELD strata ( p p =0.53), while international normalized ratio was a stronger predictor of mortality in AAH than other LT indications (HR=1.95 for AAH vs. HR=1.14 for other ALD vs. HR=1.23 for non-ALD; all p <0.001). Patients with AAH are disproportionately prioritized under the current organ allocation system, underscoring the need to revise the allocation practices to ensure equitable LT access.
- 26 June 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Meeting the demand: Incorporating living donor liver transplantation into the deceased donor liver transplantation landscape
Liver transplantation (LT) has for decades been a well-established treatment for end-stage liver disease and malignancy, becoming the standard of care for select patients with these life-limiting conditions. Due to a limited pool of high-quality deceased donor organs, there is an existing and growing disparity between those in need of and those able to access LT. Living donor liver transplantation (LDLT) has emerged as one way to mitigate this disparity. Despite Australia’s place in history as the first reported LDLT from mother-to-child in 1987, living donation for adults is rare, in part due to perceived lack of need due to the historically low waitlist mortality data. This Perspective reviews the history of LDLT and utilises Australia as a case-study for exploring the necessity for LDLT in existing deceased donor liver transplant programs, the ethical considerations, risks and benefits of the procedure, and the means to implement LDLT.
- 26 June 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Meeting the demand: Incorporating living donor liver transplantation into the deceased donor liver transplantation landscape
Liver transplantation (LT) has for decades been a well-established treatment for end-stage liver disease and malignancy, becoming the standard of care for select patients with these life-limiting conditions. Due to a limited pool of high-quality deceased donor organs, there is an existing and growing disparity between those in need of and those able to access LT. Living donor liver transplantation (LDLT) has emerged as one way to mitigate this disparity. Despite Australia’s place in history as the first reported LDLT from mother-to-child in 1987, living donation for adults is rare, in part due to perceived lack of need due to the historically low waitlist mortality data. This Perspective reviews the history of LDLT and utilises Australia as a case-study for exploring the necessity for LDLT in existing deceased donor liver transplant programs, the ethical considerations, risks and benefits of the procedure, and the means to implement LDLT.
- Open Access
- 22 April 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (5) , e1940
Outcomes of Simultaneous Liver-Kidney Transplant and Kidney After Liver Transplant Using the Safety Net Criteria—A Single-center Experience
Background.: The impact of revised Organ Procurement and Transplantation Network policy defining eligibility for simultaneous liver-kidney (SLK) and the safety net criteria for kidney after liver (KAL) transplantation remains insufficiently characterized. Methods.: We conducted a retrospective study of adults (>18 y) evaluated for liver transplant alone (LTA), SLK, or KAL at the University of Pennsylvania from August 10, 2017, to February 28, 2023. The primary outcome was mortality among SLK and KAL recipients and those patients waitlisted for KAL. Secondary outcomes included native kidney recovery in LTA recipients, estimated glomerular filtration rate (eGFR) at 1 y post-kidney transplant, and time between liver and kidney transplants. Results.: Of 1655 patients evaluated, 57 (3.4%) met SLK criteria; 49 (86%) underwent SLK and 8 (14%) received LTA. Among 1598 LTA candidates, 1010 (63%) were waitlisted and 717 (71%) received LTA. After excluding 9 early deaths (1.3%) that were unrelated to KAL delay, 67 survivors (9.5%) met KAL safety net criteria. Thirty-four (50.8%) were waitlisted (15 transplanted over a median of 220 d), 30 (44.8%) declined, and 3 (4.8%) remained under evaluation. Mortality was 4.1% after SLK and no deaths occurred after KAL >3.7 and 3.1 y of follow-up, with 3 deaths (8.8%) among KAL waitlisted patients. Of the 16 KAL waitlisted patients alive without kidney transplant at last follow-up, 2 (12.5%) were delisted after documented renal recovery and an additional 9 (56.3%) had eGFR >20 ml/min/1.73 m 2 and were being considered for delisting; together, 11 (68.8%) met predefined criteria for substantial native kidney recovery. One-year median eGFR was similar (SLK 51 versus KAL 54 mL/min/1.73 m 2 ; P = 0.6). Conclusions.: Early post-LTA mortality was unrelated to delayed KAL transplantation. Recovery of native kidney function while waiting for KAL was frequent. KAL transplants occurred within a year of LTA with favorable survival and graft outcomes.
- 22 April 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (5) , e1940
Open AccessOutcomes of Simultaneous Liver-Kidney Transplant and Kidney After Liver Transplant Using the Safety Net Criteria—A Single-center Experience
Background.: The impact of revised Organ Procurement and Transplantation Network policy defining eligibility for simultaneous liver-kidney (SLK) and the safety net criteria for kidney after liver (KAL) transplantation remains insufficiently characterized. Methods.: We conducted a retrospective study of adults (>18 y) evaluated for liver transplant alone (LTA), SLK, or KAL at the University of Pennsylvania from August 10, 2017, to February 28, 2023. The primary outcome was mortality among SLK and KAL recipients and those patients waitlisted for KAL. Secondary outcomes included native kidney recovery in LTA recipients, estimated glomerular filtration rate (eGFR) at 1 y post-kidney transplant, and time between liver and kidney transplants. Results.: Of 1655 patients evaluated, 57 (3.4%) met SLK criteria; 49 (86%) underwent SLK and 8 (14%) received LTA. Among 1598 LTA candidates, 1010 (63%) were waitlisted and 717 (71%) received LTA. After excluding 9 early deaths (1.3%) that were unrelated to KAL delay, 67 survivors (9.5%) met KAL safety net criteria. Thirty-four (50.8%) were waitlisted (15 transplanted over a median of 220 d), 30 (44.8%) declined, and 3 (4.8%) remained under evaluation. Mortality was 4.1% after SLK and no deaths occurred after KAL >3.7 and 3.1 y of follow-up, with 3 deaths (8.8%) among KAL waitlisted patients. Of the 16 KAL waitlisted patients alive without kidney transplant at last follow-up, 2 (12.5%) were delisted after documented renal recovery and an additional 9 (56.3%) had eGFR >20 ml/min/1.73 m 2 and were being considered for delisting; together, 11 (68.8%) met predefined criteria for substantial native kidney recovery. One-year median eGFR was similar (SLK 51 versus KAL 54 mL/min/1.73 m 2 ; P = 0.6). Conclusions.: Early post-LTA mortality was unrelated to delayed KAL transplantation. Recovery of native kidney function while waiting for KAL was frequent. KAL transplants occurred within a year of LTA with favorable survival and graft outcomes.
- 21 April 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (11) , 1512-1522
Delisting for clinical improvement as a proxy for recompensated cirrhosis on the U.S. liver transplant waitlist: A retrospective cohort study
Background & Aims: Recompensation is emerging as a concrete outcome for patients with effective disease-modifying treatments for cirrhosis. Delisting due to clinical improvement (DCI) from the liver transplant (LT) waitlist may serve as a proxy for recompensation. This study investigated factors associated with time on the waitlist and risk of relisting. Approach & Results: This was a retrospective cohort study of patients listed for LT between 1/1/2005-12/31/2024 using the Organ Procurement and Transplantation Network (OPTN) database. Timing of DCI was categorized as: p p <0.001). Conclusions: The occurrence of DCI is variable across disease etiologies. Achieving combined improvement in MELD and CTP class may better identify durable clinical improvement and guide safe waitlist removal decisions.
- 21 April 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (11) , 1512-1522
Delisting for clinical improvement as a proxy for recompensated cirrhosis on the U.S. liver transplant waitlist: A retrospective cohort study
Background & Aims: Recompensation is emerging as a concrete outcome for patients with effective disease-modifying treatments for cirrhosis. Delisting due to clinical improvement (DCI) from the liver transplant (LT) waitlist may serve as a proxy for recompensation. This study investigated factors associated with time on the waitlist and risk of relisting. Approach & Results: This was a retrospective cohort study of patients listed for LT between 1/1/2005-12/31/2024 using the Organ Procurement and Transplantation Network (OPTN) database. Timing of DCI was categorized as: p p <0.001). Conclusions: The occurrence of DCI is variable across disease etiologies. Achieving combined improvement in MELD and CTP class may better identify durable clinical improvement and guide safe waitlist removal decisions.
- 27 February 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (7) , 1040-1048
Heterogeneity in liver transplantation practices for critically ill patients with chronic liver disease in the U.S.
Liver transplantation (LT) in critically ill patients with chronic liver disease is a high-risk procedure. Recent studies show that the frequency of intensive care unit (ICU) LTs has risen, and outcomes of such transplants have improved significantly. Variation in practices and the impact of center experience with ICU LTs on outcomes is unknown outside of acute liver failure (ALF). This study evaluated the impact of center experience with ICU LT on outcome metrics. Using the United Network for Organ Sharing database, we conducted a retrospective analysis of adult liver transplants performed 2014–2023 in which the patient was in an ICU before transplant, excluding those listed for multiorgan, retransplant, or ALF. Critical care requirements, in-hospital, 1-year, and 3-year mortality, and retransplant were compared by center ICU LT volume quartiles. In total, 9542 ICU LTs were performed across 130 centers (12.8% of total LTs). Over half of U.S. centers performed fewer than 5 ICU LTs per year on average, while the centers in the highest quartile performed nearly two-thirds of all ICU LTs in this period. Utilization of dialysis and of concurrent critical care therapies in ICU LT recipients was higher at high-volume centers ( p 0.05). Adjusting for severity of illness, center volume of ICU LTs in the prior year was associated with a small but significant reduction in 1-year post-ICU LT mortality: aOR 0.96 per 5 ICU LTs ( p <0.001). Expansion of LT for ICU candidates does not appear to threaten center-based metrics and may even offer important benefits to future candidates.
- 27 February 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (7) , 1040-1048
Heterogeneity in liver transplantation practices for critically ill patients with chronic liver disease in the U.S.
Liver transplantation (LT) in critically ill patients with chronic liver disease is a high-risk procedure. Recent studies show that the frequency of intensive care unit (ICU) LTs has risen, and outcomes of such transplants have improved significantly. Variation in practices and the impact of center experience with ICU LTs on outcomes is unknown outside of acute liver failure (ALF). This study evaluated the impact of center experience with ICU LT on outcome metrics. Using the United Network for Organ Sharing database, we conducted a retrospective analysis of adult liver transplants performed 2014–2023 in which the patient was in an ICU before transplant, excluding those listed for multiorgan, retransplant, or ALF. Critical care requirements, in-hospital, 1-year, and 3-year mortality, and retransplant were compared by center ICU LT volume quartiles. In total, 9542 ICU LTs were performed across 130 centers (12.8% of total LTs). Over half of U.S. centers performed fewer than 5 ICU LTs per year on average, while the centers in the highest quartile performed nearly two-thirds of all ICU LTs in this period. Utilization of dialysis and of concurrent critical care therapies in ICU LT recipients was higher at high-volume centers ( p 0.05). Adjusting for severity of illness, center volume of ICU LTs in the prior year was associated with a small but significant reduction in 1-year post-ICU LT mortality: aOR 0.96 per 5 ICU LTs ( p <0.001). Expansion of LT for ICU candidates does not appear to threaten center-based metrics and may even offer important benefits to future candidates.
- 19 February 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (2) , 337-339
Stains in primary biliary cholangitis: Untangling promise from bias
An abstract is unavailable. This article is available as a PDF only.
- 19 February 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (2) , 337-339
Stains in primary biliary cholangitis: Untangling promise from bias
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 23 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (24) , 3174-3188
Cardiac sarcoidosis: new insights beyond the granuloma using spatial proteomics
Background and Aims: Cardiac sarcoidosis (CS) is poorly understood, challenging to diagnose, and portends a poor prognosis. A lack of animal models necessitates the use of residual human samples to study sarcoidosis, which in turn necessitates the use of analytical tools compatible with archival, fixed tissue. This study employed high-plex spatial protein analysis to characterize the immunologic, fibrotic, and metabolic landscape of CS. Methods: Cardiac tissues from 64 patients—39 with CS and 25 without CS (Controls)—were analysed using the GeoMx Digital Spatial Profiler. Regions of interest (ROIs) with and without granulomatous inflammation were selected to examine protein abundance. ROIs were further divided into areas of illumination to separately analyse distinct protein profiles in myocytes, stroma, and vessels. A 79-protein panel was used to characterize immune and parenchymal cell populations. Differential protein abundance was evaluated using mixed-effects modeling. A predictive model was developed using a subset of seven proteins to distinguish inflammation-free CS ROIs from control ROIs. Results: Spatial profiling demonstrated marked heterogeneity within and between sarcoidosis granulomas. Inflammation-free ROIs from CS hearts exhibited a ‘distance gradient’, with protein abundance varying by proximity to granulomatous inflammation. The seven-protein predictive model achieved 95.9% accuracy and an area under the receiver operating characteristic curve of 0.993 in differentiating inflammation-free CS ROIs from Controls. Conclusions: Spatial proteomics revealed novel features of the CS microenvironment and identified a distinct immune signature in tissue lacking overt inflammation. These findings may improve diagnostic accuracy in clinical biopsies from patients with suspected CS.
- 23 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (24) , 3174-3188
Open AccessCardiac sarcoidosis: new insights beyond the granuloma using spatial proteomics
Background and Aims: Cardiac sarcoidosis (CS) is poorly understood, challenging to diagnose, and portends a poor prognosis. A lack of animal models necessitates the use of residual human samples to study sarcoidosis, which in turn necessitates the use of analytical tools compatible with archival, fixed tissue. This study employed high-plex spatial protein analysis to characterize the immunologic, fibrotic, and metabolic landscape of CS. Methods: Cardiac tissues from 64 patients—39 with CS and 25 without CS (Controls)—were analysed using the GeoMx Digital Spatial Profiler. Regions of interest (ROIs) with and without granulomatous inflammation were selected to examine protein abundance. ROIs were further divided into areas of illumination to separately analyse distinct protein profiles in myocytes, stroma, and vessels. A 79-protein panel was used to characterize immune and parenchymal cell populations. Differential protein abundance was evaluated using mixed-effects modeling. A predictive model was developed using a subset of seven proteins to distinguish inflammation-free CS ROIs from control ROIs. Results: Spatial profiling demonstrated marked heterogeneity within and between sarcoidosis granulomas. Inflammation-free ROIs from CS hearts exhibited a ‘distance gradient’, with protein abundance varying by proximity to granulomatous inflammation. The seven-protein predictive model achieved 95.9% accuracy and an area under the receiver operating characteristic curve of 0.993 in differentiating inflammation-free CS ROIs from Controls. Conclusions: Spatial proteomics revealed novel features of the CS microenvironment and identified a distinct immune signature in tissue lacking overt inflammation. These findings may improve diagnostic accuracy in clinical biopsies from patients with suspected CS.
- 22 December 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (1) , e70249
The Landscape of Status 1B by Exception for Pediatric Acute on Chronic Liver Failure—High Risk, High Mortality, and Low Transplant Rate
Background: Acute on chronic liver failure (ACLF) leads to increased mortality from multiorgan failure. Methods: Our objective was to evaluate differences in characteristics and outcomes of children with ACLF listed as Status 1B for liver transplantation (LT) by (1) explicit criteria or (2) exception. We identified 367 children with ACLF who were listed Status 1B for LT in the United Network for Organ Sharing (UNOS) database between January 2007 and March 2019. Children with metabolic diseases and malignancies were excluded. Results: Of 367 children with ACLF listed as Status 1B, 110 (30%) were listed by exception. There were no differences between groups in age, sex, race/ethnicity, or diagnosis. Incidence of cumulative organ failures and MELD/PELD scores were lower in the exception group at waitlisting and at waitlist removal (all p < 0.05). There were regional differences in exception utilization with regions 2 and 10 having a higher proportion of exception listing (43% and 47% vs. overall 30%, p = 0.03). There was no difference in transplantation rate, recovery without transplant, or pre−/post‐LT mortality between groups. Narrative summaries in the exception group cited the critical or refractory nature of the patient's illness, with increased risk of waitlist mortality as reasons for urgent LT. Conclusion: Our study showed that one third of children with ACLF listed as Status 1B receive this designation using exception criteria. Children listed by exception had similar pre−/post‐LT mortality compared to the explicit group. Further study is needed to understand why these children are at higher risk than expected.
- 22 December 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (1) , e70249
The Landscape of Status 1B by Exception for Pediatric Acute on Chronic Liver Failure—High Risk, High Mortality, and Low Transplant Rate
Background: Acute on chronic liver failure (ACLF) leads to increased mortality from multiorgan failure. Methods: Our objective was to evaluate differences in characteristics and outcomes of children with ACLF listed as Status 1B for liver transplantation (LT) by (1) explicit criteria or (2) exception. We identified 367 children with ACLF who were listed Status 1B for LT in the United Network for Organ Sharing (UNOS) database between January 2007 and March 2019. Children with metabolic diseases and malignancies were excluded. Results: Of 367 children with ACLF listed as Status 1B, 110 (30%) were listed by exception. There were no differences between groups in age, sex, race/ethnicity, or diagnosis. Incidence of cumulative organ failures and MELD/PELD scores were lower in the exception group at waitlisting and at waitlist removal (all p < 0.05). There were regional differences in exception utilization with regions 2 and 10 having a higher proportion of exception listing (43% and 47% vs. overall 30%, p = 0.03). There was no difference in transplantation rate, recovery without transplant, or pre−/post‐LT mortality between groups. Narrative summaries in the exception group cited the critical or refractory nature of the patient's illness, with increased risk of waitlist mortality as reasons for urgent LT. Conclusion: Our study showed that one third of children with ACLF listed as Status 1B receive this designation using exception criteria. Children listed by exception had similar pre−/post‐LT mortality compared to the explicit group. Further study is needed to understand why these children are at higher risk than expected.